<DOC>
	<DOCNO>NCT00963547</DOCNO>
	<brief_summary>This study find maximum tolerate dose MK2206 combination trastuzumab trastuzumab/lapatinib patient HER2+ breast cancer solid tumor .</brief_summary>
	<brief_title>A Study MK2206 Combination With Trastuzumab Lapatinib Treatment HER2+ Solid Tumors ( 2206-015 )</brief_title>
	<detailed_description />
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Patient histologically cytologicallyconfirmed locally advanced metastatic HER2+ solid tumor Female patient negative pregnancy test Patient able swallow tablet Patient chemotherapy , radiotherapy biological therapy within 4 week screen . Patients receive trastuzumab and/or lapatinib prior screening must medications 1 week prior first dose MK2206 trastuzumab administer 2 mg/kg weekly 3 week trastuzumab administer 6 mg/kg weekly Patient primary CNS tumor know active CNS metastases Patient history evidence heart disease Patient poorly control high blood pressure diabetes Patient pregnant breastfeeding expect conceive father child study Patient HIV positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Documented HER2+</keyword>
</DOC>